Definitive Contract 75N93025C00013
Award Date
2/1/25
Potential Completion Date
4/10/25
Potential Value
$1.5M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Avantgen Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92121, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $356,021 firm-fixed-price definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services' National Institutes of Health (NIH), to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies for ferret biomarkers. This work is set aside for small businesses. Avantgen has previously received NIH contracts to develop rapid diagnostic...
This is a $592,751 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Avantgen Inc., a San Diego-based biotechnology company. The contract is for the development of rabbit monoclonal antibodies to serve as biomarkers for the Indian Flying Fox (bat) virus. There is no set-aside designation for this contract. Avantgen has previously worked with NIAID and other federal agencies on the development of rapid test kits,...
This $199,987 fixed-price contract was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Avantgen Inc., a small business biotechnology company based in San Diego, California. The contract is for the development of recombinant rabbit monoclonal antibodies to be used as affinity captures for peptides. This work supports the agency's research and development efforts in cancer immunotherapy. The contract was set aside for small businesses and has a...
This is a $747,441.00 cost-plus-fixed-fee definitive contract awarded by the National Cancer Institute to Avantgen Inc., a small business based in San Diego, CA. The contract is for a Small Business Innovation Research (SBIR) Phase II project titled "Recombinant Antibodies as Affinity Captures" under Topic 288. The goal is to develop recombinant antibodies for use in affinity capture applications. This contract builds upon Avantgen's prior SBIR Phase I and II awards from the...
This $596,519 fixed-price federal contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Ampersand Biosciences LLC, a woman-owned small business. The contract is for the development of reagents to support immunologic analysis of non-mammalian and underrepresented mammalian models, such as ferrets and mice, under SBIR Topic 107. This aligns with NIAID's mission to conduct and support research to...
The Defense Health Agency awarded a $84,720.53 firm fixed price purchase order to Genovac Antibody Discovery LLC, a small disadvantaged business, for the generation of monoclonal antibodies targeting ferret immunoglobulin M and immunoglobulin G. This requirement was solicited as a 100% small business set-aside. The contract has an ultimate completion date of December 29, 2023 and was awarded on May 1, 2023. The contract was issued under a federal contract opportunity posted on April 7, 2023...
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...
This is a federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. government, to Abviro LLC, a for-profit limited liability company, on September 19, 2016. The contract is for the development of a broad-spectrum antibody therapeutic against flavivirus infections, with a ceiling value of $29,404,716.25 and a completion date of September 30, 2022. The contract type is a Definitive Contract with a Cost Plus Fixed Fee pricing...
Ampersand Biosciences LLC has been awarded a $572,817 firm fixed price contract by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to develop ferret reagents for use in characterizing immune responses to respiratory infections in the ferret disease model. The contract is associated with the Small Business Innovation Research Program Phase I solicitation and will support the prime contractor's work through August 2022. The total award has been set...
This is a firm fixed-price purchase order valued at $7,017.50 awarded by the National Institute of Allergy and Infectious Diseases (NIAID) within the Department of Health and Human Services (HHS) to Affymetrix, Inc. for the delivery of antibodies. The contract does not have a set-aside designation. The award indicates that Affymetrix, Inc. is registered in the System for Award Management (SAM) until March 2018 and is classified as a for-profit manufacturer of goods. No additional details...